Clinical trial
Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)
NCT00405184 · CSL Limited, Industry · Completed
Key facts
| NCT number | NCT00405184 |
|---|---|
| Title | Ig NextGen 10% in Patients With Primary Immune Deficiency (PID) |
| Official title | A Multi-centre, Open-label, Cross-over Study to Compare the Pharmacokinetics, Safety and Tolerability of Ig NextGen 10% With Intragam P in Patients With Primary Immune Deficiency (PID) |
| Lead sponsor | CSL Limited, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Immune Deficiency (PID) |
| Intervention type | Drug |
| Interventions | IntragamP, Ig NextGen 10% |
| Enrollment | 19 |
| Start date | May 1, 2007 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Nov 29, 2006 |
| Last update posted | Jun 7, 2012 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: